New method helps see early brain changes linked to Alzheimer's

Important: This is not a ready-made diagnostic test or a "judgement". The new indicator assesses similarity to a known disease pattern and potential risk, but by itself does not mean that a person will necessarily get sick.

Details

The method is called the Regional Vulnerability Index, or RVI-AD. It was developed by researchers from the University of Texas Health Science Center, UTHealth Houston School of Behavioral Health Sciences, Keck School of Medicine of USC and University of Maryland School of Medicine. The work is published in Molecular Psychiatry.

The idea of the method is not to look for one single "dangerous" place in the brain, but to assess the overall pattern of changes. To do this, the scientists used large arrays of neuroimaging data of people with and without Alzheimer's disease. On this basis, they identified a typical pattern of changes associated with the disease.

An individual person's brain can then be compared to this pattern. The RVI-AD index takes into account parameters such as the volume, thickness and size of different brain regions. The more closely the MRI data matches the "Alzheimer's-like" pattern, the higher the index.

The authors emphasise that early changes in Alzheimer's disease can form long before noticeable symptoms - before memory, attention or everyday thinking deteriorate. Therefore, the researchers want to use such indices for earlier risk assessment, including in adults who do not yet have cognitive complaints.

Why it matters

Alzheimer's disease is usually diagnosed when a person already has noticeable memory and thinking impairments. But by that point, changes in the brain can take many years to develop. That's why scientists are increasingly looking for ways to detect the risk earlier - before symptoms are evident.

A potential advantage of RVI-AD is that it works with MRI, a non-invasive and more accessible method than some other ways of assessing biomarkers, such as PET scans or analysing cerebrospinal fluid.

If this approach is validated in further studies, it could help doctors spot people at higher risk earlier and work more closely with factors that are associated with dementia: cardiovascular health, lifestyle, heredity and other parameters.

Background

Different types of biomarkers are now being studied for Alzheimer's disease: brain changes on MRI and PET scans, indicators in cerebrospinal fluid, blood tests, genetic factors and digital markers. Each approach has its own limitations in terms of cost, availability, accuracy and applicability in routine clinical practice.

RVI-AD belongs to a field where data from large neuroimaging studies are trying to be translated into an understandable individualised measure. But for now, it is a research tool. It cannot be perceived as an independent diagnosis of Alzheimer's disease in a particular person.

Source

The study by Peter Kochunov and co-authors Alzheimer's disease-like brain pattern biomarker: capturing risks and predicting disease onset is published in Molecular Psychiatry in 2026. The authors developed the RVI-AD index, which assesses the similarity of a person's brain structure to patterns characteristic of Alzheimer's disease.